Literature DB >> 10731277

Elevation of defibrillation thresholds with propofol during implantable cardioverter-defibrillator testing.

T J Cohen1, T Chengot, C Quan, A P Peller.   

Abstract

A 26-year-old man with severe dilated cardiomyopathy and frequent ventricular tachycardia treated with propafenone plus mexiletine underwent implantable cardioverter-defibrillator testing one day after dual chamber defibrillator implantation. There were no significant changes in the R-wave and lead position on chest x-ray. Routine defibrillator threshold (DFT) testing after 320 mg intravenous propofol demonstrated high DFTs (greater than 31 Joules and requiring 360 Joules externally for termination). Change in polarity failed to improve DFTs. After about 20 minutes of washout, conscious sedation was performed with 20 mg of midazolam and repeat DFTs were equal to 21 Joules. This case demonstrates the potential for an acute dose dependent rise in DFT with propofol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731277

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  4 in total

1.  Effects of propofol sedation on pacing thresholds : Results from an observational cohort study.

Authors:  Jakob Lüker; Arian Sultan; Tobias Plenge; Samuel Lee; Jan-Hendrik van den Bruck; Daniel Steven
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-11-14

Review 2.  Effect of drugs on defibrillation capacity.

Authors:  Anna Legreid Dopp; John M Miller; James E Tisdale
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  High defibrillation threshold: the science, signs and solutions.

Authors:  Sony Jacob; Victorio Pidlaoan; Jaspreet Singh; Aditya Bharadwaj; Mehul B Patel; Antonio Carrillo
Journal:  Indian Pacing Electrophysiol J       Date:  2010-01-07

4.  Comment on "Sedative and Analgesic Effects of Entonox Gas Compared with Midazolam and Fentanyl in Synchronized Cardioversion".

Authors:  Henrique Horta Veloso
Journal:  Crit Care Res Pract       Date:  2016-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.